EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of Gastric or GEJ Adenocarcinoma and Oesophageal Squamous Cell Carcinoma

New indications concern patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and oesophageal squamous cell carcinoma

Source